MMV 21st call for proposals -2023

MMV welcomes proposals in the following areas:

1. Compounds having activity against Plasmodium falciparum blood stages in vitro (TCP1-TPP1) for use in treatment or chemoprevention (TCP1-TPP2)

2. Compounds addressing the key priorities of the malaria eradication agenda (TCP3, and TCP6)

3. Novel families of molecules in the hit-to-lead or lead optimization stages, without G6PD deficiency liabilities

Funding and duration not specified. 

Research Authority due date: 23.3.23

LOI (required) due date: 31.3.23
Full proposal upon request only.